Vertex Pharmaceuticals Incorporated (VRTX)

Market Cap	114.71B
Revenue (ttm)	11.72B
Net Income (ttm)	3.68B
Shares Out	253.72M
EPS (ttm)	14.22
PE Ratio	31.79
Forward PE	22.55
Dividend	n/a
Ex-Dividend Date	n/a

Volume	824,668
Open	454.34
Previous Close	453.36
Day's Range	448.52 - 455.99
52-Week Range	362.50 - 519.68
Beta	0.32
Analysts	Buy
Price Target	497.77 (+10.09%)
Earnings Date	Feb 9, 2026

About VRTX

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 24, 1991
• Employees: 6,100
• Stock Exchange: NASDAQ
• Ticker Symbol: VRTX
• Website: https://www.vrtx.com

Analyst Summary

According to 24 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price target is $497.77, which is an increase of 10.09% from the latest price.

Price Target

$497.77

(10.09% upside)

Analyst Consensus: Buy